The UK’s top cardiologist told the conference in Venice that the introduction of semaglutide – sold under the brand names Wegovy and Ozempic – could be the biggest medical breakthrough since statins.
He said anyone with a Body Mass Index of at least 27 – millions of people in the UK – should therefore be recommended semaglutide if they wanted to improve their overall cardiovascular health, not just to target weight loss. Prevalence appears to be higher in areas of greater deprivation and among people with disabilities, lower levels of education or of Black ethnicity. There are more than 11,000 hospital admissions each year directly attributable to obesity.
CVD affects around seven million people in the UK and is a significant cause of disability and death. It is responsible for one in four premature deaths in the UK and accounts for the largest gap in health life expectancy. “Around half of the patients that I see in my cardiovascular practice have levels of weight equivalent to those in the trial and are likely to derive benefit from taking semaglutide on top of their usual level of guideline-directed care,” Professor Deanfield said.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: medical_xpress - 🏆 101. / 51 Read more »
Source: TheSun - 🏆 64. / 61 Read more »
Source: medical_xpress - 🏆 101. / 51 Read more »
Source: SkyNews - 🏆 35. / 67 Read more »